primary antibodies for glut4  (Cell Signaling Technology Inc)

Journal: Maxillofacial plastic and reconstructive surgery

Article Title: Therapeutic potential of 4-hexylresorcinol in reducing sarcopenia in diabetic masseter muscle.

doi: 10.1186/s40902-025-00457-w

Figure Lengend Snippet: Fig. 4 Immunohistochemical analysis of Glut4 and p-AMPKα expression in masseter muscle cross-sections from diabetic rats with and without 4HR treatment. Photomicrographs of masseter muscle cross-sections stained with anti-Glut4 and anti-p-AMPKα specific antibodies are shown (scale bar = 50 μm; images without counterstaining). The expression levels of Glut4 and p-AMPKα were significantly higher in the STZ/4HR group compared to the STZ group (*P < 0.05, **.**P < 0.001), indicating that 4HR treatment enhances Glut4 and p-AMPKα expression in diabetic muscle tissue (original magnification × 200)

Article Snippet: To investigate the expression of specific proteins in the masseter muscle tissues, we conducted immunohistochemical staining using primary antibodies targeting Glut4 (catalog number sc-53566) from Santa Cruz Biotechnology (Santa Cruz, CA, USA), as well as p-AMPKα (catalog number 07–6814) from Merck (Rahway, NJ, USA).

Techniques: Immunohistochemical staining, Expressing, Staining

Journal: Heliyon

Article Title: Naringenin enhances the efficacy of ferroptosis inducers by attenuating aerobic glycolysis by activating the AMPK-PGC1α signalling axis in liver cancer

doi: 10.1016/j.heliyon.2024.e32288

Figure Lengend Snippet: Primer sequences information.

Article Snippet: Specific primary antibodies against GLUT4 (66846-1-Ig), Cyclin D1 (60186-1-Ig), Cyclin E1 (11554-1-AP) were purchased from Proteintech (Wuhan, China); LDHA (YN033) and GLUT1 (YT1928) were purchased from Immunoway (Hunan, China); PGC1α (#2178) was purchased from CST (Massachusetts, USA); β-actin (ab8227), PDK-1 (ab207450), p-AMPKα1/2 (ab133448), AMPKα1/2 (ab207442), CDK6 (ab124821), CDK2 (ab32147) were purchased from Abcam (United Kingdom).

Techniques:

Journal: Heliyon

Article Title: Naringenin enhances the efficacy of ferroptosis inducers by attenuating aerobic glycolysis by activating the AMPK-PGC1α signalling axis in liver cancer

doi: 10.1016/j.heliyon.2024.e32288

Figure Lengend Snippet: Naringenin inhibits aerobic glycolysis in liver cancer cells. HepG2 cells were treated with Nar (0.1 mM/0.2 mM) and/or erastin (5 μM)/RSL3 (0.1 μM). (A) The glucose uptake levels of the cell. (B) Cellular lactate production. (C)the intracellular ATP level of the cells. (D) Western blot was utilized to determine the protein expression levels of GLUT1, GLUT4, LDHA, and PDK1 in HepG2 cells. (E) qRT-PCR was utilized to determine the mRNA expression levels of GLUT1, GLUT4, LDHA, and PDK1 in HepG2 cells. *P < 0.05, **P < 0.01, ***P < 0.001, n = 3 per group.

Article Snippet: Specific primary antibodies against GLUT4 (66846-1-Ig), Cyclin D1 (60186-1-Ig), Cyclin E1 (11554-1-AP) were purchased from Proteintech (Wuhan, China); LDHA (YN033) and GLUT1 (YT1928) were purchased from Immunoway (Hunan, China); PGC1α (#2178) was purchased from CST (Massachusetts, USA); β-actin (ab8227), PDK-1 (ab207450), p-AMPKα1/2 (ab133448), AMPKα1/2 (ab207442), CDK6 (ab124821), CDK2 (ab32147) were purchased from Abcam (United Kingdom).

Techniques: Western Blot, Expressing, Quantitative RT-PCR